BiolActis develops and commercializes novel innovative and clinically proven Biologics meeting well identified needs from the Wellness Industries.
BiolActis transforms substrate proteins by means of an innovative process of fermentation that leads to products promoting homeostatic regulation of complex metabolic disorders. The products are value-added Multi Plex Matrices in the Lactoceuticals family, an original classification term coined by BiolActis. The company’s technological advances allow to concentrate and to synergize the biologically active components of fermented proteins in one single matrix. BiolActis benchmarks its products against established pharmaceutical drugs and believes in a general metabolic/nutritional approach.
Metabolic Syndrome and Homeostasis
Much disease results from disturbance of homeostasis, a condition known as homeostasis imbalance. In humans, this will result in the metabolic cascade diseases including: weight gain, diabetes, blood fat disorders, hypertension and chronic inflammation. Learn more »
Products
BiolActis has developed several Multi Plex Matrices (MPM) indicated for various types of metabolic disorders. The company offers a pipeline of potential products protected by Patent Estate and Trademarks. Learn more »
Clinical Trials
BiolActis carries out a series of Clinical Trials in human carefully supervised, approved by Regulatory Authorities and Ethics Committees, to evaluate each MPM, determine how it acts and whether it is safe and effective in the target human population. Learn more »
Latest News
- January 16, 2008 - Technologie Biolactis announces the filing of a new Patent protecting a major discovery with respect to the modulation of the Immune System: "Method for regulating TH17 Pathway".